



GenomeCanada

**Genome Canada - Notice of Award**  
**2014 Large-Scale Applied Research Project Competition**  
***Genomics and Feeding the Future***

**June 22, 2015**

---

**Lead Genome Centre:** Genome British Columbia

**Project Leader(s):** Rieseberg and Burke

**Project Title:** Genomics of Abiotic Stress Resistance in Wild and Cultivated Sunflowers

---

The Board of Directors of Genome Canada has approved funding for this project to a maximum of \$7,879,009 over four years, of which Genome Canada's maximum contribution is \$3,054,485.

The Board of Directors of Genome Canada approved funding for 11 out of 27 projects. Because the funding for the recommended projects was greater than the budget available, the Board approved that Genome Canada's financial contribution to each project be reduced by 5%. When calculating the maximum budget recommended, the 5% reduction was applied to each project following removal of any budget items associated with the elimination of specific scientific activities, as recommended by the review committee, and ineligible expenses, as identified through the due diligence review. Additional adjustments may also be required subsequent to follow-up by staff on other issues raised through the due diligence review. **The scope of the project, including objectives and milestones must not be adjusted as a result of this 5% reduction.**

Before funds can be disbursed, several conditions for funding must be satisfied and are detailed below.

As leader(s) of an approved project, you must demonstrate that you have satisfied all conditions and will be in a position to receive Genome Canada funding by **September 30, 2015**. In order to ensure that all conditions are met by this time, the following revised documents should be submitted to Genome Canada by **August 17, 2015**: budget; co-funding strategy; and objectives and milestones (where required).

***Genome Canada reserves the right to withdraw funding for any approved project that is not ready to receive funding by September 30, 2015.***

Prior to the disbursement of funds, Genome Canada requires:

- i. A letter signed by the CEO of the Genome Centre confirming to Genome Canada that: all agreements have been signed between the Genome Centre, Genome Canada, the lead organization, the researchers and the co-funding partners; all other conditions for release of funds have been met; and funds will flow to the project upon receipt of funds from Genome Canada. The agreements must clearly demonstrate agreement among the relevant parties, on all significant issues including but not limited to, the nature of financial contributions, IP ownership and management, data release, the commercialization process, project management, ethics and biohazard certification, the role of the Research Oversight Committee (ROC - see below), the funding term, a termination policy, financial and administrative policies,



quarterly reporting of expenses and co-funding status. The agreements must be in compliance with the agreement between Genome Canada and the lead Genome Centre.

- ii. A revised budget: A revised budget will be required in instances where there are budget implications arising from recommendations of the review panel or due diligence review (as outlined in the Summary of Review), as well as where there are reductions in costs of services. To account for the 5% reduction in Genome Canada's financial contribution, one budget line is to be added at the end of the detailed budget, with the corresponding negative amount, under the largest activity and expense, and with Genome Canada as the 'Source of Funds'. Genome Canada will NOT accept revisions to the budget for any other reasons. Final budget approval will be based on a review by Genome Canada. Consideration must also be given to the following issues:
  - a) *Changes in the Cost of Services*. Given that the cost of services may have changed since the project was submitted for review, projects must provide an updated statement of work (SOW) which reflects the current cost of services, or a written confirmation from service providers that the cost of services remains unchanged. The current cost estimates should be used in the revised budget and the budget reduced accordingly.
  - b) *Ineligible Institutions*. *Genome Canada funds cannot* flow to Federal government labs or industry with the exception of costs incurred on a reasonable fee for service arrangement or contract.
- iii. An updated co-funding strategy that demonstrates secured co-funding (received or firmly committed) amounting to a minimum of 75% of the co-funding for eligible costs and a well-developed and feasible plan for securing the remaining 25% of co-funding.
- iv. Acknowledgement that appropriate certification for proposals performing research involving human subjects, human stem cells, animals, biohazards, radioactive materials or possible effects on the environment is in place. Certification must be obtained specifically for the research approved for funding by Genome Canada. In order to release funds to an organization, Genome Canada will accept a letter from the appropriate officials at the organization confirming that:
  - a) the organization will ensure that all relevant certifications are obtained in accordance with applicable laws, regulations, standards and guidelines, including but not limited to, the most current versions of the following: Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS); CIHR Guidelines for Human Pluripotent Stem Cell Research; Canadian Council of Animal Care (CCAC) guidelines and policies; Canadian Environmental Assessment Act; Public Health Agency of Canada's Laboratory Biosafety Guidelines; and Canadian Food Inspection Agency Containment Standards for Veterinary Facilities;
  - b) the organization will not flow funds to an investigator until all relevant certifications are obtained for the research to be undertaken; and,
  - c) the organization will provide Genome Canada with copies of certifications, upon request.
- v. A [Data Release and Resource Sharing](#) plan approved by Genome Canada. The project must remain current with internationally accepted standards for data release and resource sharing.
- vi. A publication policy which includes a commitment to comply with Genome Canada's policy on [Access to Research Publications](#).



GenomeCanada

- vii. A commitment to acknowledge the contribution of the Government of Canada through Genome Canada and the lead Genome Centre, as well as all other relevant funders in research publications, as well as all communications including press releases, posters and oral presentations. In addition, visual presentations such as seminars and websites must include the Genome Canada logo in compliance with Genome Canada's [Brand Standards Guide](#).
- viii. Meet other conditions that may be set by the Board of Directors of Genome Canada.
- ix. Meet specific conditions or recommendations of the Review Committee as detailed in the project's Summary of Review and Status Report.
- x. Agree to the guidelines for the administration of projects as outlined in Genome Canada's [Guidelines for Funding Research Projects](#).

### **Research Oversight Committee (ROC)**

Each project must have a Research Oversight Committee (ROC), which will be tasked with reporting to the Genome Centre on progress being made by the project. The ROC will make recommendations regarding continued funding and will provide advice and guidance to the research team to help ensure that the project achieves its milestones within the framework of the approved budget. The Lead Genome Centre is responsible for establishing and managing the project's ROC, taking into account recommendations from other Genome Centres that have a substantive financial investment in the project. Additional details on the requirements of the ROC can be found in the [ROC Terms of Reference](#).

### **Accountability, Reporting and Performance Measurement**

Funded projects must submit to their lead Genome Centre information and data as prescribed by the Centre in terms of timing, format and content, which will allow for the on-going assessment and monitoring of their performance. Funded projects must also agree to participate in and provide information for any evaluation-type activities that may be undertaken from time to time by Genome Canada or the Genome Centre, for up to five years subsequent to the end date of the project.

### **Management of Changes to Genome Canada-Funded Projects**

Over the term of a Genome Canada-funded project, adjustments can be expected to the initially approved project, because of required changes to the scientific, managerial or financial conditions of funding initially approved by Genome Canada. In order to manage these adjustments, funded projects must follow the principles outlined in Genome Canada's "Guidelines for the Management of Changes to Genome Canada-Funded Projects".

### **Final Reports**

Within three (3) months of the completion of the projects, each project will be required to submit to its Genome Centre a final report that includes a description of the accomplishments of the project relative to the approved objectives as well as a financial settlement report in a format determined by Genome Canada. The latter will enable Genome Canada to determine its prorated share of actual expenses in the approved budget. A percentage of the total advances will be withheld by the Genome Centres, pending approval of the final report.

Rieseberg

	Total Budget	GC Contribution	% <sup>1</sup>	Description of Adjustments		
Request Amount	8,039,771	3,215,247				
Adjustments :						
Sub-Total	8,039,771	3,215,247				
G&A 5% Max. (Overage)			3.9%	298,350	387,071	88,721
Sub-Total	8,039,771	3,215,247		Adj. request <sup>2</sup>	Maximum	Reduction if ( )
GC 40% Max. (Overage)						
Sub-Total	8,039,771	3,215,247	40.0%			
GC 5% Reduction <sup>3</sup>	(160,762)	(160,762)				
<b>Maximum Amount</b>	<b>7,879,009</b>	<b>3,054,485</b>	<b>38.8%</b>			

Notes :

1. Percentage indicated is after adjustments.
2. Original request for G&A expenses less adjustments, if applicable.
3. The overall reduction is calculated as 5% of the GC contribution after adjustments.